基于FAERS数据库的droxidopa不良事件信号的探索和评估
Xinnan Chen1, Haohao Zhu2, Ying Jiang2
1School of Pediatrics, Nanjing Medical University, Nanjing, China.
Expert opinion on drug safety
|January 6, 2025
概括
这项研究使用FAERS数据确定了与Droxidopa相关的新不良事件. 感染和感染,包括尿路感染和肺炎,需要提高临床警.
科学领域:
- 药物监督 药物监督 药物监督
- 现实世界的数据分析分析.
- 药物安全监督监督是对药物安全的监督.
背景情况:
- 使用食品和药物管理局的不良事件报告系统 (FAERS) 进行现实世界的数据分析.
- 调查与Droxidopa相关的潜在不良事件.
- 为临床实践和药物安全提供必要的参考信息.
研究的目的:
- 在现实环境中探索与Droxidopa相关的潜在不良事件.
- 识别超出现有药物标签的新型安全信号.
- 为临床实践提供信息,并指导未来关于Droxidopa安全性的研究.
主要方法:
- 收集了FAERS (2014年第三季度 - 2023年第四季度) 的不良事件报告,其中Droxidopa是主要的疑似药物.
- 采用多种信号量化技术:比例报告比率 (PRR),报告几率比率 (ROR),贝叶斯信任传播神经网络 (BCPNN) 和最小玛波森偏差 (MGPS).
- 选了19,295份与droxidopa相关的报告,分析了27个系统器官类别中的94个首选术语.
主要成果:
- 确定了超出Droxidopa已知的副作用的新不良事件信号.
- 新的信号包括胃肠道疾病,感染和感染,肌肉骨和结缔组织疾病.
- 特别突出 尿路感染, 尿路感染 假名, 和 肺炎 愿望 在 感染 和 感染 中, 需要提高临床警.
结论:
- 已经确定了与Droxidopa相关的新的潜在不良事件.
- 强调需要保持谨慎,特别是在感染和病方面.
- 建议进行进一步的研究,以验证这些新发现的安全信号,并告知临床管理.
相关概念视频
01:19Pharmacovigilance
730
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
730
01:25Drug Regulation
1.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.2K
01:11Clinical Trials: Overview
2.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.4K
01:29Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
01:24Parkinson's Disease: Treatment
148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148